Visugromab Antibody

SKU: orb1943900

Description

Visugromab (CTL-002) is a GDF-15-neutralizing monoclonal antibody. It demonstrates synergistic antitumor efficacy in combination with anti-PD-1 therapy like Nivolumab, showing promise in preclinical models for treating PD-1/PD-L1 refractory metastatic cancers.

Research Area

Cell Biology, Immunology & Inflammation, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2556646-63-8
• MW: 144.50 kDa
• Purity: 95.00%
• Target: TGF-beta/Smad,PD-1/PD-L1

Bioactivity

• In Vivo:
  In preclinical toxicology studies on cynomolgus monkeys, Visugromab (maximum dose of 100 mg/kg, weekly) did not exhibit any signs of toxicity.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PDL1, PD-L1, CTL002, CTL-002, PD1/PDL1, PD1, PD-1

Quick Database Links

Gene Symbol

TGF-beta/Smad,PD-1/PD-L1